VCM
MRKR icon

Versant Capital Management’s Marker Therapeutics MRKR Stock Holding History

Versant Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15
Closed -$13 – 2709
2025
Q3 		$13 Hold
15
– – ﹤0.01% 2634
2025
Q2 		$23 Hold
15
– – ﹤0.01% 2625
2025
Q1 		$18 Hold
15
– – ﹤0.01% 2507
2024
Q4 		$47 Hold
15
– – ﹤0.01% 2366
2024
Q3 		$42 Hold
15
– – ﹤0.01% 1996
2024
Q2 		$81 Hold
15
– – ﹤0.01% 1936
2024
Q1 		$65 Hold
15
– – ﹤0.01% 1867
2023
Q4 		$83 Hold
15
– – ﹤0.01% 1900
2023
Q3 		$68 Hold
15
– – ﹤0.01% 1930
2023
Q2 		$47 Hold
15
– – ﹤0.01% 2039
2023
Q1 		$11 Hold
15
– – ﹤0.01% 1766
2022
Q4 		$40 Hold
15
– – ﹤0.01% 1645
2022
Q3 		$0 Hold
15
– – ﹤0.01% 1561
2022
Q2 		$0 Hold
15
– – ﹤0.01% 1566
2022
Q1 		$0 Hold
15
– – ﹤0.01% 1565
2021
Q4 		$0 Hold
15
– – ﹤0.01% 1535
2021
Q3 		$0 Hold
15
– – ﹤0.01% 1540
2021
Q2 		$0 Buy
+15
New +$395 ﹤0.01% 1540

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Versant Capital Management's MRKR Position: Q4 2025 in Review

Versant Capital Management sold out of Marker Therapeutics (MRKR) in Q4 2025, closing a stake of 15 shares — an estimated $13 sold.

Versant Capital Management first reported a position in MRKR in Q2 2021 and held it in 18 quarters. The position peaked at $83 in Q4 2023. 36 funds tracked by Wall St. Rank hold MRKR as of Q4 2025.

  • Versant Capital Management reported no remaining Marker Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Versant Capital Management sold 15 Marker Therapeutics shares in Q4 2025, an estimated $13.
  • Versant Capital Management first reported a position in Marker Therapeutics in Q2 2021 and held it in 18 quarters.
  • Versant Capital Management's Marker Therapeutics position peaked at $83 in Q4 2023.
  • 36 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2025.

Based on Versant Capital Management's 13F filing for Q4 2025, filed 8 Jan 2026.